Randy Vogenberg 2013
Drug shortages might cause more drug substitutions which, in turn, could increase the chances of adverse events and the legal ramifications that go with them, says F. Randy Vogenberg, RPh, PhD. Newly created accountable care organizations need to be wary.
P&T committees will have to consider the economic fallout from their decisions as health reform advances, says F. Randy Vogenberg, RPh, PhD. That will be an adjustment.
F. Randy Vogenberg, RPh, PhD, a member of P&T’s Editorial Board, says that in the fixed reimbursement system under health reform, pharmacists will need to balance clinical and economic considerations. The less expensive drug might not always be the answer.
Insurance coverage was never meant to handle new pharmaceutical breakthroughs on the radar — breakthroughs that can cost anywhere from $90,000 to $300,000 a year per patient, says F. Randy Vogenberg, RPh, PhD, principal of the Institute for Integrated Healthcare and a member of P&T’s Editorial Board. There will be pressure on everybody to find a way to somehow control these costs.